Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia ; volume:14 ; number:1 ; day:31 ; month:1 ; year:2024 ; pages:1-11 ; date:12.2024
Scientific reports ; 14, Heft 1 (31.1.2024), 1-11, 12.2024
- Urheber
-
Woźniak, Ewelina
Broncel, Marlena
Woźniak, Agnieszka
Satała, Joanna
Pawlos, Agnieszka
Bukowska, Bożena
Gorzelak-Pabiś, Paulina
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-52571-w
- URN
-
urn:nbn:de:101:1-2024041316365945480201
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Woźniak, Ewelina
- Broncel, Marlena
- Woźniak, Agnieszka
- Satała, Joanna
- Pawlos, Agnieszka
- Bukowska, Bożena
- Gorzelak-Pabiś, Paulina
- SpringerLink (Online service)
Ähnliche Objekte (12)
P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study
Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey
Familial Hypercholesterolemia: new therapeutic approaches
Sex Differences in Familial Hypercholesterolemia
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
Clinical and molecular genetic characterization of patients with familial hypercholesterolemia
Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
Familial Hypercholesterolemia: Present and Future Management
The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia
P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study
Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey
Familial Hypercholesterolemia: new therapeutic approaches
Sex Differences in Familial Hypercholesterolemia
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
Clinical and molecular genetic characterization of patients with familial hypercholesterolemia
Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
Familial Hypercholesterolemia: Present and Future Management
The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia
P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study
Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey
Familial Hypercholesterolemia: new therapeutic approaches
Sex Differences in Familial Hypercholesterolemia
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
Clinical and molecular genetic characterization of patients with familial hypercholesterolemia
Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
Familial Hypercholesterolemia: Present and Future Management